On August 7, 2025, MetaVia Inc. (MTVA) announced financial results for the second quarter of 2025 and provided a business update. The company recently announced the extension of the 48 mg cohort from the Phase 1 trial of DA-1726, a dual GLP1/GCGR agonist, to 8-weeks in order to evaluate longer-term early efficacy and safety. We anticipate results from this cohort before the end of 2025. In addition, MetaVia is working to conduct an 'End-of-Phase 2' meeting with the FDA regarding next steps for DA-1241, an oral GPR119 agonist being developed for the treatment of MASH. While MASH will remain the near-term focus for DA-1241's development, the company has signed a collaboration agreement with Syntekabio to use its AI platform to identify potential additional targets for DA-1241.
